WILLIAM J PHD LINK
CIK 1228684 · last filed 2026-06-29
WILLIAM J PHD LINK is a corporate insider who has filed 103 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for TARS, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$31.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $166.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$166.87M
11
103
-$30.99M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TARS | Director | 108,714 | $58.95 | $6.41M | -$5.96M | 21 | 2026-06-29 |
| RXST | Director | 96,140 | $6.05 | $581.6K | -$903.1K | 17 | 2026-06-18 |
| LNSR | Director | 568,062 | $5.35 | $3.04M | $0 | 7 | 2026-06-05 |
| Oyster Point Pharma, Inc. (OYST) Delisted | Director | 38,008 | $11.17 | $424.5K | -$7.72M | 9 | 2022-01-07 |
| GKOS | Director | 58,300 | $151.33 | $8.82M | -$7.62M | 17 | 2021-06-07 |
| EW | Director | 51,162 | $83.68 | $4.28M | -$7.03M | 15 | 2020-05-11 |
| Vivani Medical, Inc. (EYESW) Delisted | Director | 4,608,161 | $0.22 | $1.01M | $0 | 3 | 2019-06-05 |
| EYES | Director | 4,515,622 | $26.58 | $120.01M | $0 | 2 | 2016-06-03 |
| INGN | Director | 3,695,816 | $6.42 | $23.73M | $0 | 1 | 2014-02-21 |
| HELICOS BIOSCIENCES CORP (HLCS) Delisted | 10%+ Owner | 10,709,818 | — | — | $4.38M | 1 | 2009-09-21 |
| INTRALASE CORP (ILSE) Delisted | Director | 2,338,482 | — | — | -$6.13M | 1 | 2007-01-17 |
Recent Filings
103 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-29 | TARS | Grant (A) | — | $0 | EDGAR |
| 2026-06-18 | RXST | Grant (A) | +37,037 | $0 | EDGAR |
| 2026-06-17 | TARS | Sell (S) | −12,500 | -$776.5K | EDGAR |
| 2026-06-16 | TARS | Exer (M) | +2,954 | $0 | EDGAR |
| 2026-06-15 | TARS | Notice (144) | −12,500 | -$776.5K | EDGAR |
| 2026-06-05 | LNSR | Grant (A) | +17,421 | $0 | EDGAR |
| 2026-03-18 | TARS | Sell (S) | −12,500 | -$859.8K | EDGAR |
| 2025-12-17 | TARS | Sell (S) | −22,946 | -$1.86M | EDGAR |
| 2025-12-15 | TARS | Notice (144) | −10,446 | -$846.3K | EDGAR |
| 2025-12-15 | TARS | Notice (144) | −12,500 | -$1.02M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.